A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with ...

Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...

The term "nonalcoholic fatty liver disease" (NAFLD) has long been used to describe liver steatosis not related to excessive alcohol consumption ...

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 in ...

But it might also trigger feelings of nausea. Another theory is that GLP-1s (glucagon-like peptide-1 receptor agonists) — the ...

New research found that some anti-obesity medications such as Wegovy and Zepbound may prompt people to drink less. These ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

Study: Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review. Image Credit: Kmpzzz/Shutterstock.com In a recent study published ...

Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...